#BEGIN_DRUGCARD DB00369

# AHFS_Codes:
Not Available

# ATC_Codes:
J05AB12

# Absorption:
100%

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
HPMPC
Vistide

# CAS_Registry_Number:
113852-37-2

# ChEBI_ID:
3696

# Chemical_Formula:
C8H14N3O6P

# Chemical_IUPAC_Name:
({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. [Wikipedia]

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Anti-HIV Agents
Antineoplastic Agents
Antiviral Agents
Radiation-Sensitizing Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.9

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
=170 mg/mL at pH 6-8

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Cidofovir

# HET_ID:
Not Available

# Half_Life:
2.4 to 3.2 hours

# InChI_Identifier:
InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1

# InChI_Key:
InChIKey=VWFCHDSQECPREK-LURJTMIESA-N

# Indication:
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

# KEGG_Compound_ID:
C06909

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
369

# Mechanism_Of_Action:
Cidofovir acts through the selective inhibition of viral DNA polymerase.Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.

# Melting_Point:
480 Â°C

# Molecular_Weight_Avg:
279.187

# Molecular_Weight_Mono:
279.062021707

# Organisms_Affected:
Human Immunodeficiency Virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448997

# Pharmacology:
Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis.

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-1.4

# Predicted_Water_Solubility:
1.15e+01 g/l

# Primary_Accession_No:
DB00369

# Protein_Binding:
6%

# PubChem_Compound_ID:
60613

# PubChem_Substance_ID:
46506054

# RxList_Link:
http://www.rxlist.com/cgi/generic2/cidofovir.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00148

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CDV
Cidofovir Anhydrous

# Synthesis_Reference:
Not Available

# Toxicity:
Kidney damage, fall in the number of white blood cells, decreased platelets

# Update_Date:
2013-02-08 16:19:17 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cidofovir

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
TYMP

# Phase_1_Metabolizing_Enzyme_1_ID:
3936

# Phase_1_Metabolizing_Enzyme_1_Name:
Thymidine phosphorylase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Thymidine phosphorylase
MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPEPKQLPELIRMKRDGGRLSEADIRGFVAA
VVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQQLEWPEAWRQQLVDKHSTGG
VGDKVSLVLAPALAACGCKVPMISGRGLGHTGGTLDKLESIPGFNVIQSPEQMQVLLDQA
GCCIVGQSEQLVPADGILYAARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAA
VFPNQEQARELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHALEVEEALLCMDGAGPP
DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQGVDPGLARAL
CSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLALVLHELGAGRSRAGEPLRLGVG
AELLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSDRAPFAAPSPFAELVLPP
QQ

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P19971

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16048917	Magee WC, Hostetler KY, Evans DH: Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother. 2005 Aug;49(8):3153-62.
16304146	Gilbert C, Boivin G: New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure. Antimicrob Agents Chemother. 2005 Dec;49(12):4860-6.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17913252	Sergerie Y, Boivin G: Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes. Antiviral Res. 2007 Sep 17;.
19275707	Andrei G, De Clercq E, Snoeck R: Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X17403

# Drug_Target_1_GenBank_ID_Protein:
1780831

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
UL54

# Drug_Target_1_Gene_Sequence:
>3729 bp
TCAACAGCATTCGTGCGCCTTGACACTGTACGGCAGAAAAGCCGGCTCCAAGTGCAAGCG
CCGCGGCAGCACCATGTGCAAAAACTTGTCCTTGCGCGCGGTTTCGCCGCCGGGAAAGAC
GGGCGACAGCACGTTAGTTACAGCCTTGAGAACCTGCTCAAAGTACTTGTCGGCGTGAAT
GGGCACGCCGTGCTCGCGCACGTAGCTCGGATCTTCGGCTACCTCGTAGTTGCACACGGC
CGACGGTGGTTTCCGCGCCCTCTTCTTTGCCGGCTCTCCTCCTCTCCTGTTGCTCTCCTC
TACCCCGCCGCCGTCAGCGTCGTCGTCCGTGCCATCAATCGCGTCCGACCGGGAAACCAC
GCCGGCGGTTACAGAATCACCGTTGTCGGAGGAACCCTGCGGCGCCGTCCGGACACCGGG
CGCCGTCAGAACGTAAAAGACCCGATCCCCGACCGAGGGTAGCTCCTCAGAACGGGCCGC
CAATCGCTTAATGACGGCAATGTGCGGCAGGTTAGATTGACGGTACAGCGAGATGTCCTT
AGAGAGCACCGACGAAAGCACCAGGTCCTCGACACGCACACGGTGCAGGTACAGATCGTC
GCGGGCCTGCACCAAGCGGCGTAAGATACGCCAGAAACCGCGTGGCACGCCGTACTTCTT
GACTTCATCGAGTGAGAGGCGCGACAGGCGCACGGCTGCTTCCGAGACCTCGCGATCCTC
AAAGAGCAGCGAGAGGACGTCACGCGTGACGCCCTTGACGAACTCGCAGGCCGTCTTGCG
CACCAGATCCACGCCCTTCATGCTCAGACCCGAGGCGCCCTCCACTTTGCCGATGTAACG
TTTCTTGCAGATCATCATAAGAGAGACGAAGACCTTTTCAAACTCCAGCTTGACGGGCTC
CACAAAAAGACAGGCCGTCACGTAGTGCGCCAGGCTGGGCCCACGCGCCACCAGAGCCTG
CGGCGTCAGGCCACGAAAGCGGACAAACACGCTGTCCGTGTCCCCGTAGATGACCCGCGC
CTCCACCCGCCGTTCGTTCGAGCCCCCTGACGATGTTTCGAGCCCCTCCGGTAACGCGCT
GCTCTCCTCCGAATCCCCCTCCCGCGTTCCCACTACATAGTCTTCCTGATTAAAAAAATT
GTGCAAAAAACACGGCTCTGAAAAGTTGTCTTTGATGAACCGCGCCGTGCGCTCTAGCAT
GTCGCGACCGATGCGCGTGATGCTGGCGGCGATGGGCAGACACGGCATCATACCGTTGAC
CACGCCGGTAAAACCGTAGAAAGCGTTGCACGTTACTTTGAGCGCCATCTGTTCCTTGTC
GAGCAGCATACGGCGCACAGGGTCTTGACACTCGCGCATGCATTCGCGCACGGCACGCCG
CTGCGAAACCCACTTGTTGAGCAGTTCCGAGAGCACCGAGACGCGCACCGAAGCACGCAC
AAAGCGGTGGGTCACGCCGTTCTCTAGCGTGACGCTGTATACGTCGGCGGGGTCCACAGG
GTACTCGCCACCCGGCACCAGCAGGGTGGAGTAGCAGAGGTTGTGGGCCATGATGATGGA
AGGGTAGAGGCTGGCAAAGTCGAACACGGCCACGGGGTCGTTGTAGTAACCCACCTCGGG
CTCAAACACCGTGGCGCCCTGGTACGAAACCGCCGCAGTACCGCCGGCGCCGTGATTGTC
GTTGGAAACGCCGACGCCGCCACTACTGCCGGAGCCGACGCTGAAAACGCCGACGCTGCT
ACTACTGTTACTGCCGGAGCCGGGTGAAACGCCGTCCTGACTGGACGGCGCAGATTGCAA
GGGCGGCGACATCTGAAACATAGCCGCCACAGAACCCGCGTCGCCGGGCACAGCGGCGGT
AGAGATGATAGCAGCGTTAGGTGACACAGCAACGCTATTCGTTTCGGGCACCGTCGTACC
TTTGCTGTAGTGGTTGGGCAGGATAAAATCGCGGCAGGCGCACTCGTCCAGCAGCGAGGT
GTAGATACGGATCTGCTGTCCGTCAAAGATGACACGCCGCAACGGAATTTTAGCCAGCCG
CGCGATGGCCCCGGCCTCGTAGTGAAAATTAATGGTGTTGAACAGATCGCGCACCAATAC
GGCGTCCTGCAGACAGTAACGGCCTACCTGGGCGCGGCCCTCGGCATTAGCCACGAAACA
ACGCGGGATGTCCTTGTAAGACAGGTCATCCTTGCGTTGCCGCAGGTAAAGCTCGGCCAT
AGTGTTGAGCTTATAGTTGGGCGAGTTAGTCTTGGCCATGCATACAGGGTACATGTCGAT
AACCACCGAACCCGCAATATACACCTTGGTGGCGGCCGTGCTGGCCGGATTGTTGTGAGA
AGCCGAGGGAAAAGCGGCGGCGTACTGCCGCTTAAAACCCACGGCGGGGCTGTGTAAAAA
GAAACGGCCGCCCTGCGCCGTAGGCAACTTGCAGAAGCGCTGCGAGTCCACCTTATACAG
GTACTCGAGACGCGTGAGGATGTACTTCAAGTCAAAAGAGTTGATGTTGTAACCGGTCAC
AAAGGCCGGCGCGTACCGTTGAAAGAAAAGCATAAAGCCCAGCAGCAGCTCGTATTCGGA
AGGGAACTCGTAGACGTCCACGTCTGGGCCCACCTGCCCGCAGGTGCCGATCGTAAAGAG
ATGAAGACCCGAGTGCCCAAAGATCACACCCTCCGAAGTGCAGCCCCGACCATCGTTCCC
GTTTGGGATCCCCTGATCCACGGCGGTGTTTCCCCCCGTCTCGTAGCACACGCACGAGAT
CTGAATGACAATGTCATCGGACTTCTCGGCGCAGGGAAAACCACCCTCGCCGCTCATGCA
CTCGATATCGAAGGACAGGCATCGATAGCGCGGCCACGAGCTGTCGTCGGGCACAGCCAC
CAGGTCAGAGACATCGCAGTCTACCTCGATATCACAAGTCGACGCGCGACCCTGCTGCCG
CCAGTCGTAACGATTCACGGAGCACCAGCCGAACGTGGTGATCCGCCGATCGATGACCAA
ACGCGTCAGCGGATCCACACGGACCTCGTACACGGGAAAACCCTGCTCCAGCAGATACTC
GCCGATTTTTCTGGCCATGGTCCAGTTGCTGATAGACACACACTGCAAATCGGGCACGGG
TCGCGTCCCGTACCCATAGATGGAGGTCTTGGTGGCCGGCGTGACAGACACGGCGTATGG
CGTCCGCGGTTCGGGCACTAGTTCGCCCACGCTGGCAATGACCTCACGCAGCCTATCGGT
GTCGCTGTACTCACAGTAAAAGTAGCTGCGCTGCCCGAAAACGTTGACGCAGATACTGTA
GCCGTGTTCTGTGGCCCCGAAGAAACGCAACACGTTCCCCGAAGGCACCAGATGCTGACG
ATAGCGCGGCGACACGTTTTCGGGCGAGTCGAAGAAGAGCACGGCGTCCGTCTGATCGTA
GGTGTGAAAACGAATAGGTCCCACCACGCGACCCACCAGGGTCTCGCGCCAAGGACACGG
CCAAACCATGTCATGACTCAACAAATGTTTAATCTCTCGATAGAACATGAGAGGCAGCCG
TCCCGTCTTATGCTTGATCAACCCCGTCTGACCGTCGAACATGACACCTCGCGGCACGAT
CTGCAAAAACTGTTTCTGTGGCGGCCGCTTGCCCGAGCCCTGCGCGGAGCCGGGCTGCGA
ACGCTGACGCCGGCCACCCGCGACCGCACCGCCGGTCACGCCGCCGCTCAGATACGGGTT
GAAAAACAT

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
12533697	Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS: The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol. 2003 Jan;84(Pt 1):17-28.
2161319	Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA 3rd, Kouzarides T, Martignetti JA, et al.: Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125-69.
3023690	Kouzarides T, Bankier AT, Satchwell SC, Weston K, Tomlinson P, Barrell BG: Sequence and transcription analysis of the human cytomegalovirus DNA polymerase gene. J Virol. 1987 Jan;61(1):125-33.
3029980	Kouzarides T, Bankier AT, Satchwell SC, Weston K, Tomlinson P, Barrell BG: Large-scale rearrangement of homologous regions in the genomes of HCMV and EBV. Virology. 1987 Apr;157(2):397-413.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
379

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
137103

# Drug_Target_1_Name:
DNA polymerase

# Drug_Target_1_Number_of_Residues:
1242

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00136	DNA_pol_B
PF03104	DNA_pol_B_exo

# Drug_Target_1_Protein_Sequence:
>DNA polymerase
MFFNPYLSGGVTGGAVAGGRRQRSQPGSAQGSGKRPPQKQFLQIVPRGVMFDGQTGLIKH
KTGRLPLMFYREIKHLLSHDMVWPCPWRETLVGRVVGPIRFHTYDQTDAVLFFDSPENVS
PRYRQHLVPSGNVLRFFGATEHGYSICVNVFGQRSYFYCEYSDTDRLREVIASVGELVPE
PRTPYAVSVTPATKTSIYGYGTRPVPDLQCVSISNWTMARKIGEYLLEQGFPVYEVRVDP
LTRLVIDRRITTFGWCSVNRYDWRQQGRASTCDIEVDCDVSDLVAVPDDSSWPRYRCLSF
DIECMSGEGGFPCAEKSDDIVIQISCVCYETGGNTAVDQGIPNGNDGRGCTSEGVIFGHS
GLHLFTIGTCGQVGPDVDVYEFPSEYELLLGFMLFFQRYAPAFVTGYNINSFDLKYILTR
LEYLYKVDSQRFCKLPTAQGGRFFLHSPAVGFKRQYAAAFPSASHNNPASTAATKVYIAG
SVVIDMYPVCMAKTNSPNYKLNTMAELYLRQRKDDLSYKDIPRCFVANAEGRAQVGRYCL
QDAVLVRDLFNTINFHYEAGAIARLAKIPLRRVIFDGQQIRIYTSLLDECACRDFILPNH
YSKGTTVPETNSVAVSPNAAIISTAAVPGDAGSVAAMFQMSPPLQSAPSSQDGVSPGSGS
NSSSSVGVFSVGSGSSGGVGVSNDNHGAGGTAAVSYQGATVFEPEVGYYNDPVAVFDFAS
LYPSIIMAHNLCYSTLLVPGGEYPVDPADVYSVTLENGVTHRFVRASVRVSVLSELLNKW
VSQRRAVRECMRECQDPVRRMLLDKEQMALKVTCNAFYGFTGVVNGMMPCLPIAASITRI
GRDMLERTARFIKDNFSEPCFLHNFFNQEDYVVGTREGDSEESSALPEGLETSSGGSNER
RVEARVIYGDTDSVFVRFRGLTPQALVARGPSLAHYVTACLFVEPVKLEFEKVFVSLMMI
CKKRYIGKVEGASGLSMKGVDLVRKTACEFVKGVTRDVLSLLFEDREVSEAAVRLSRLSL
DEVKKYGVPRGFWRILRRLVQARDDLYLHRVRVEDLVLSSVLSKDISLYRQSNLPHIAVI
KRLAARSEELPSVGDRVFYVLTAPGVRTAPQGSSDNGDSVTAGVVSRSDAIDGTDDDADG
GGVEESNRRGGEPAKKRARKPPSAVCNYEVAEDPSYVREHGVPIHADKYFEQVLKAVTNV
LSPVFPGGETARKDKFLHMVLPRRLHLEPAFLPYSVKAHECC

# Drug_Target_1_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P08546

# Drug_Target_1_SwissProt_Name:
DPOL_HCMVA

# Drug_Target_1_Synonyms:
EC 2.7.7.7

# Drug_Target_1_Theoretical_pI:
7.33

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00369
